v3.26.1

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Operating expenses:
Research and development	$ 63,981	$ 183,867
General and administrative	552,138	695,788
Total operating expenses	616,119	879,655
Loss from operations	(616,119)	(879,655)
Other income (expense):
Other income	14,000	42,000
Interest income	6	5
Interest expense on loan payable	(10,001)	(6,954)
Non-cash interest expense on convertible notes	(73,332)	(73,533)
Accretion to redemption value on convertible notes	0	(1,446)
Total other income, net	(69,327)	(39,928)
Loss before provision for income taxes	(685,446)	(919,583)
Provision for income taxes	2,400	2,400
Net loss	$ (687,846)	$ (921,983)
Basic loss per common share	$ (0.10)	$ (0.13)
Diluted loss per common share	$ (0.10)	$ (0.13)
Weighted average number of common shares outstanding – basic	7,236,447	7,236,447

Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481639/420-10-35-4

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482017/420-10-50-1

Mosaic ImmunoEngineering Inc. 10-K